Brooklyn ImmunoTherapeutics (BTX) – Press Releases
-
Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates
-
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer
-
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
-
Brooklyn ImmunoTherapeutics Announces Board Changes
-
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Po
-
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q
-
Amarin Announces Appointment of New Directors and Board Leadership Changes
-
Amarin Announces Appointment of New Directors and Board Leadership Changes
-
Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
-
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results
-
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement
-
Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement
-
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors
-
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
-
Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
-
Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index
-
Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences
-
Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Quality
-
Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition
-
Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results
-
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq
-
Brooklyn ImmunoTherapeutics Reports Inducement Grants
-
Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer
-
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021
-
Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts
-
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET
-
Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience
-
Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum
-
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021
-
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET
-
Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results
-
Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021
-
Theragnostics Strengthens Board of Directors with Key Appointments
-
Brooklyn Immuno Reports Inducement Grants
-
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics
-
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer
-
Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021
-
Brooklyn ImmunoTherapeutics Reports Inducement Grants
-
Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics
-
Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index
-
Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. D’Amour as Chief Scientific Officer
-
Brooklyn ImmunoTherapeutics Establishes Research and Development Center in Cambridge, Massachusetts
-
Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company’s Future During May 25, 2021 Shareholder Update Call
-
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing
-
Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.
-
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET
-
Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.
-
Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research
-
Erich Mohr, Ph.D., to Join the Board of Directors of Brooklyn ImmunoTherapeutics
-
Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders
Back to BTX Stock Lookup
